Could I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning

This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding” — Dr. Alex Belser, Cybin’s Chief Clinical Officer #7. Beacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform “analyzing EEGs is labor intensive and interpretation of these tests can vary from one clinician to another..…Beacon Biosignals has assembled what it claims is one of the world’s largest clinical EEG databases. By applying its proprietary machine-learning algorithms to the database, the company says it has identified neurobiomarkers—biological indicators that are associated with certain groups of patients, drug activity, and therapeutic efficacy.” #8. Amyloid-related imaging abnormalities (ARIA) found in approximately 40% of patients taking “Alzheimer’s drug” Aduhelm Not good, yet completely predictable, and let’s remember this is for a “treatment” costing as much as $100,000/ year with exactly ZERO proven clinical benefit: “…The researchers found 425 cases in the combined aducanumab group experienced ARIA (41.3%), and ARIA-edema was identified in 362 patients or 35.2%. Of them, 94 (26%) had symptoms, such as headache, confusion, dizziness and nausea. They found ARIA-microhemorrhage and ARIA-superficial siderosis in 197 patients (19.1%) and 151 patients (14.7%), respectively.” Finally, Let’s Thank our unique Human Brains and Minds with a few ...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Education & Lifelong Learning aducanumab Aduhelm Alzheimer's drug Beacon Biosignals Click Therapeutics Cognitive Behavioral Therapy Monitoring cognitive-bias cognitive-testing curiosity Cybin depression digit Source Type: blogs